Oncternal Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.3202
- Today's High:
- $0.3452
- Open Price:
- $0.331
- 52W Low:
- $0.26
- 52W High:
- $1.33
- Prev. Close:
- $0.32
- Volume:
- 141291
Company Statistics
- Market Cap.:
- $17.70 million
- Book Value:
- 0.769
- Revenue TTM:
- $862000
- Operating Margin TTM:
- -5212.07%
- Gross Profit TTM:
- $-31490000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -42.45%
- Return on Equity TTM:
- -72.12%
Company Profile
Oncternal Therapeutics Inc had its IPO on 2004-02-03 under the ticker symbol ONCT.
The company operates in the Healthcare sector and Biotechnology industry. Oncternal Therapeutics Inc has a staff strength of 30 employees.
Stock update
Shares of Oncternal Therapeutics Inc opened at $0.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.32 - $0.35, and closed at $0.33.
This is a +1.88% increase from the previous day's closing price.
A total volume of 141,291 shares were traded at the close of the day’s session.
In the last one week, shares of Oncternal Therapeutics Inc have increased by +8.67%.
Oncternal Therapeutics Inc's Key Ratios
Oncternal Therapeutics Inc has a market cap of $17.70 million, indicating a price to book ratio of 0.8794 and a price to sales ratio of 27.6427.
In the last 12-months Oncternal Therapeutics Inc’s revenue was $862000 with a gross profit of $-31490000 and an EBITDA of $0. The EBITDA ratio measures Oncternal Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Oncternal Therapeutics Inc’s operating margin was -5212.07% while its return on assets stood at -42.45% with a return of equity of -72.12%.
In Q2, Oncternal Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 44.5%.
Oncternal Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Oncternal Therapeutics Inc’s profitability.
Oncternal Therapeutics Inc stock is trading at a EV to sales ratio of 0.8526 and a EV to EBITDA ratio of 0.2487. Its price to sales ratio in the trailing 12-months stood at 27.6427.
Oncternal Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $50.77 million
- Total Liabilities
- $4.83 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Oncternal Therapeutics Inc ended 2024 with $50.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $50.77 million while shareholder equity stood at $-178753000.00.
Oncternal Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.83 million in other current liabilities, 59000.00 in common stock, $-178753000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.83 million and cash and short-term investments were $45.50 million. The company’s total short-term debt was $145,000 while long-term debt stood at $0.
Oncternal Therapeutics Inc’s total current assets stands at $50.08 million while long-term investments were $0 and short-term investments were $29.67 million. Its net receivables were $0 compared to accounts payable of $2.22 million and inventory worth $0.
In 2024, Oncternal Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Oncternal Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.33
- 52-Week High
- $1.33
- 52-Week Low
- $0.26
- Analyst Target Price
- $1.9
Oncternal Therapeutics Inc stock is currently trading at $0.33 per share. It touched a 52-week high of $1.33 and a 52-week low of $1.33. Analysts tracking the stock have a 12-month average target price of $1.9.
Its 50-day moving average was $0.36 and 200-day moving average was $0.62 The short ratio stood at 1.36 indicating a short percent outstanding of 0%.
Around 862.3% of the company’s stock are held by insiders while 1957.4% are held by institutions.
Frequently Asked Questions About Oncternal Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.